Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.70 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.52 |
| ▸ | IL6 | P05231 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23403876 | 0.99 | TLR7 (0.69) | TLR7TLR8IL6 | |
| SCHEMBL4131529 | 0.93 | TLR7 (0.66) | TLR7TLR8 | |
| SCHEMBL31123015 | 0.93 | TLR7 (0.68) | TLR7IL6 | |
| SCHEMBL9971017 | 0.93 | TLR7 (0.68) | TLR7IL6 | |
| Hydrochloric Acid SCHEMBL31123016 | 0.92 | TLR7 (0.67) | TLR7IL6 | |
| SCHEMBL9936590 | 0.91 | TLR7 (0.69) | TLR7TLR8IL6 | |
| SCHEMBL9935626 | 0.90 | TLR7 (0.59) | TLR7IL6 | |
| Hydrochloric Acid SCHEMBL28579700 | 0.90 | TLR7 (0.68) | TLR7TLR8IL6 | |
| SCHEMBL4132555 | 0.88 | TLR7 (0.63) | TLR7TLR8IL6 | |
| SCHEMBL4131152 | 0.87 | TLR7 (0.61) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC | 2023-10-05 | — | — | US | disclosed |
| EP-2651943-A1 | PURINE DERIVATIVES | Astrazeneca AB (SE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080730-A1 | PURINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | TLR3, TLR7, TLR8 | TLR7 2/4885TLR8 3/4885IL6 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.